Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT07409428
A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL
A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor: Hutchmed
Interventions
HMPL-760 HMPL-760 Placebo R-GemOx
Updated 1 time since 2026 Last updated: Feb 6, 2026 Started: Mar 10, 2026 Primary completion: Apr 30, 2028 Completion: Dec 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE3 clinical study on Relapsed/Refractory Diffuse Large B-Cell Lymphoma, this trial is actively recruiting participants. The trial is conducted by Hutchmed and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Hutchmed
Data source: Hutchmed
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.